bims-myxlip Biomed News
on Myxoid liposarcoma
Issue of 2022–01–16
two papers selected by
Laura Mannarino, Humanitas Research
  1. Epigenetics of Cutaneous Sarcoma.
  2. EJSO educational Special issue from the TARPSWG - Standard medical treatment and new options in retroperitoneal sarcoma.
  1. Int J Mol Sci. 2021 Dec 31. pii: 422. [Epub ahead of print]23(1):
    Epigenetics of Cutaneous Sarcoma.
    Emi Mashima, Yu Sawada.
      Epigenetic changes influence various physiological and pathological conditions in the human body. Recent advances in epigenetic studies of the skin have led to an appreciation of the importance of epigenetic modifications in skin diseases. Cutaneous sarcomas are intractable skin cancers, and there are no curative therapeutic options for the advanced forms of cutaneous sarcomas. In this review, we discuss the detailed molecular effects of epigenetic modifications on skin sarcomas, such as dermatofibrosarcoma protuberans, angiosarcoma, Kaposi's sarcoma, leiomyosarcoma, and liposarcoma. We also discuss the application of epigenetic-targeted therapy for skin sarcomas.
    Keywords:  Kaposi’s sarcoma; angiosarcoma; dermatofibrosarcoma protuberans; epigenetics; leiomyosarcoma; liposarcoma; skin sarcoma
    DOI:  https://doi.org/10.3390/ijms23010422
  2. Eur J Surg Oncol. 2021 Dec 31. pii: S0748-7983(21)01437-2. [Epub ahead of print]
    EJSO educational Special issue from the TARPSWG - Standard medical treatment and new options in retroperitoneal sarcoma.
    Bernd Kasper, Giacomo Giulio Baldi, Herbert Ho-Fung Loong, Jonathan Trent.
      Retroperitoneal soft tissue sarcomas mainly consist histologically of liposarcomas and leiomyosarcomas. For the liposarcoma subgroup, the local relapse rate seems to determine patients' overall prognosis. In contrast, leiomyosarcoma patients are challenged by the development of metastatic disease; therefore, effective systemic therapies are the cornerstone to improve patients' outcome. No doubt, the limited number of active regimens currently available makes the treatment of patients with locally advanced and/or metastatic disease challenging and results in the overall poor prognosis of this population. In this European Journal of Surgical Oncology Educational Special Issue from the Transatlantic Australasian RetroPeritoneal Sarcoma Working Group (TARPSWG), we aim to summarize state-of-the-art systemic treatments for patients with retroperitoneal sarcomas with a focus on the locally advanced and metastatic disease setting including conventional standard chemotherapies as well as new innovative treatment approaches in order to identify current unmet medical needs guiding the sarcoma community to initiate appropriate translational research projects and design innovative clinical trials.
    Keywords:  Leiomyosarcoma; Liposarcoma; Research; Retroperitoneal; Systemic treatment
    DOI:  https://doi.org/10.1016/j.ejso.2021.12.465
This page is being maintained by Thomas Krichel. It was last updated on 2024‒11‒22 at 4:24.